Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

528 results about "Imaging agent" patented technology

Imaging agents are chemicals designed to allow clinicians to determine whether a mass is benign or malignant and locate metastatic cancer sites in the body. The development of an imaging agent involves synthesizing the agent to target a particular tumor or process, after which the imaging instruments can be adjusted to neutralize the target. Such agents are first examined via preclinical animal studies before engaging in early-phase human clinical studies.

Targeting ligands for disease-targeted imaging agents and methods of use therefor

In accordance with at least one aspect of this disclosure, there is provided an imaging agent, a including dye compound conjugated to an antigen specific targeting vector which can be particularly advantageous because their behavior in vivo can contribute to superior optical imaging properties, for example, by significantly increasing the target-to-background ratio of imaged tissues, leading to higher resolution imaging, and ultimately providing for better recognition of malignant tissue for resection and margin assessment and improved visualization during minimal invasive laparoscopic surgery, for example. A method of imaging tumor cells in a subject, can include, administering an imaging effective amount of an imaging agent according at least one embodiment of the invention; 2-4 hours after administration of the imaging agent, irradiating a region in the subject in which tumor cells are expected to be found with at a wavelength absorbed by the imaging agent; and detecting a signal from the imaging agent, thereby imaging the tumor cells, wherein the target-to-background ratio 2-4 hours after administration is from about 2.75 to about 15.
Owner:CURADEL SURGICAL INNOVATIONS INC

Disease-targeted imaging agents

The invention is based, at least in part, on the discovery that replacement of a key bond in the near-infrared fluorophore with a carbon-carbon bond conjugation to a targeting ligand results in vastly increased stability as compared to NIR fluorophores without such a bond, while preserving ligand and zwitterionic properties. In at least one aspect, the invention provides an imaging agent dye comprising a charge-balanced imaging agent conjugated to a targeting vector, wherein the targeting vector is a PSMA binding vector, such as dPSMA-617 or KUE, a FAP binding vector, a bombesin receptor binding vector, or a somatostatin receptor binding vector, and the charge-balanced imaging agent is ZW-800-1, ZW-830-1, or ZW-700-1-Forte.
Owner:CURADEL SURGICAL INNOVATIONS INC

Compounds for positron emission tomography

Described herein are compounds, compositions, and methods for diagnosing and / or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.
Owner:PURDUE RES FOUND +1

Radiopharmaceutical labeled precursor targeting prostate specific membrane antigen, fluorine radiolabeled compound thereof and application of fluorine radiolabeled compound

The invention discloses a class of radiopharmaceutical labeled precursors targeting prostate specific membrane antigens, the structure of the radiopharmaceutical labeled precursors is shown as the following: # imgabs0 #, a precursor reagent RESCA-PSMA-1802 targeting prostate specific membrane antigens is synthesized for the first time, the reagent can be labeled by using an 18F-Al method to prepare a positron imaging agent 18FAl-RESCA-PSMA-1802, and the reagent can be used for preparing the prostate specific membrane antigens. The polymer has good stability and biological activity in vivo and in vitro, has good targeting property on prostate cancer cells, can reflect tumor recurrence or metastasis conditions, and is very suitable for PET imaging.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Composition containing folic acid compound and near-infrared fluorescence capture system

The invention provides a composition containing folic acid compounds and a near-infrared fluorescence capture system. The near-infrared fluorescence capture system comprises an imaging module, and the imaging module comprises a compound shown in the formula I or pharmaceutically acceptable salt of the compound. The compound shown in the formula I or the pharmaceutically acceptable salt of the compound can be used as a near-infrared fluorescence imaging agent, and is good in targeting property and clinical application prospect. # imgabs0 #
Owner:DIAGPROBE BIOTECHNOLOGY (SUZHOU) CO LTD

System and method for identifying an abnormal perfusion pattern

Disclosed are systems and methods for continuously detecting, and optionally classifying, abnormal perfusion patterns in tissue by means of fluorescence imaging. A computer implemented method for detecting (and / or identifying) one or more areas having an abnormal perfusion pattern in tissue of a subject, for example during a medical procedure, includes: continuously acquiring fluorescence images of the tissue, wherein the fluorescence images are associated with a fluorescent output signal correlated with an input signal defined by a series of boluses of at least one fluorescent imaging agent, and wherein the series of boluses is administered with a predefined and / or controlled duration between subsequent boluses, analyzing the fluorescence images, identifying at least one tissue area with normal perfusion, defining a normal perfusion pattern (in an intensity domain and) in a time domain, and detecting, in the fluorescence images, possible tissue areas with abnormal (non-normal) perfusion pattern.
Owner:PERFUSION TECH APS

Targeting Her2 nuclide probe and preparation method and application thereof

The invention provides a target Her2 nuclide probe as well as a preparation method and application thereof, and relates to the technical field of nuclide probes. The target Her2 nuclide probe comprises a compound which is labeled by radionuclide and is shown in a formula I. The target Her2 nuclide probe can be used as a diagnosis and treatment reagent in human or animal Her2 protein high expression lesions, and is especially used as a tumor imaging agent and a radionuclide treatment drug. In animal experiments, the tumor / muscle ratio of the radioactive complex is high, and the radioactive complex has a good application prospect. And the formula I of the # imgabs0 # is shown in the specification.
Owner:NANJING NUOYUAN MEDICAL DEVICES CO LTD

Novel metal oxide nanoparticles for use as radiosensitizer or for visualizing

The present invention relates to the nanoparticles (NP) of the invention, compositions thereof and their use as therapeutic agents, in particular in the field of oncology and / or as imaging agents. The NPs consist of first nanoparticles of at least one high-Z metal oxide material, to which smaller second nanoparticles are covalently bonded at the surface of the first nanoparticles. The second nanoparticles consist of a) at least one noble metal or at least one metal oxide, metal sulfide, metal selenide or metal sulfide / selenide as a Fenton or Fenton-like reaction catalyst. The NPs of the invention produce a surprising therapeutic effect when exposed to ionizing radiation such as X-rays, gamma-rays, protons, neutrons, radioisotopes and / or electron beams. Therefore, these NPs can be used as radiosensitizers in the field of oncology. These nanoparticles can also be used as contrast agents.
Owner:NANOBIOTIX SA

Auxiliary diagnosis and treatment system based on large-scale language model

The invention discloses an auxiliary diagnosis and treatment system based on a large-scale language model, and belongs to the technical field of medical image analysis, and the auxiliary diagnosis and treatment system comprises a medical image agent based on a large-scale pre-training language model, a tool assembly and a storage pool module, the tool assembly comprises a report generation module, an image segmentation module, a focus detection module, a report evaluation module, a diagnosis and treatment assistant module and a storage pool module. According to the auxiliary diagnosis and treatment system based on the large-scale language model, natural languages input by a user are analyzed and converted into specific task prompts through the medical image intelligent body, complex medical image problems are automatically decomposed, tool assemblies are matched and called, detailed step-by-step solutions are generated, and compared with an existing device, the auxiliary diagnosis and treatment system based on the large-scale language model has the advantages that the efficiency is high; the problem that the operation is complex and not visual enough is avoided, the operation is simplified, and the use threshold is lowered.
Owner:安徽影联云享医疗科技有限公司 +3

Nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents

An “inverse” precipitation route to precipitate aqueous soluble species with copolymers as nanoparticles having a hydrophilic, polar core and a less polar shell is described.
Owner:THE TRUSTEES OF PRINCETON UNIV

CT-traced tumor radiotherapy embolism microspheres and preparation method and application thereof

PendingCN119097759AAchieve combined radiotherapy and chemotherapyImprove imaging effectSurgical adhesivesX-ray constrast preparationsMeth-Polyvinyl alcohol
The invention relates to preparation and application of a tumor radiotherapy embolism microsphere preparation capable of achieving CT imaging tracing. The microsphere is prepared by taking a polyvinyl alcohol derivative as a framework material, polymerizing, cross-linking and curing the polyvinyl alcohol derivative and an N-(aminoalkyl) methacrylamide hydrochloride monomer, and further covalently connecting a metal chelating agent and a CT imaging agent 2, 3, 5-triiodobenzaldehyde. The microsphere can mark radionuclides 111ln, 68Ga, Al18F, 64Cu, 177Lu and 90Y, embolism treatment and radionuclide internal irradiation treatment are combined, meanwhile, the microsphere CT tracing function is beneficial to monitoring the distribution condition of the microsphere in real time, and ectopic embolism is reduced.
Owner:FUDAN UNIV SHANGHAI CANCER CENT

Targeted PARP diagnosis and treatment integrated reagent based on combined administration strategy

The invention discloses a targeted PARP diagnosis and treatment integrated reagent based on a combined administration strategy, and provides the targeted PARP diagnosis and treatment integrated reagent based on the combined administration strategy, and the targeted PARP diagnosis and treatment integrated reagent can be used as a tracer agent and an imaging agent in nuclear medicine and is used for treating PARP expressing cancers, especially various disease states of pancreatic cancer.
Owner:NANJING MEDICAL UNIV

Radiopharmaceutical MOFs for medical imaging

The present invention relates to MOFs for use in imaging and as radiolabeled tracers. More specifically, the present invention provides particles comprising MOFs, optionally at least one targeting moiety, and at least one short-lived radionuclide; compositions comprising the particles; the particles or compositions for use as imaging agents; the particles or compositions for use in methods for diagnosing proliferative diseases; the particles or compositions for use in methods for diagnosing chronic inflammatory diseases; and kits comprising particles comprising MOFs, optionally a targeting moiety, and a short-lived radionuclide cation.
Owner:ノード ファルマ アクシェセルスカープ

FAP-Targeted Radiopharmaceuticals and Imaging Agents and Related Uses

The tumor stroma, which accounts for a large portion of the tumor mass, is an attractive target for the delivery of diagnostic and therapeutic compounds. Here, we focus specifically on a subpopulation of stromal cells known as cancer-associated fibroblasts, which are present in over 90% of epithelial cancers, including pancreatic, colon, and breast cancers. Cancer-associated fibroblasts are characterized by high expression of FAPs, which are undetectable in adult normal tissues but are associated with poor prognosis in cancer patients. The present invention provides small molecule radiopharmaceuticals and imaging agents based on FAP-specific inhibitors.
Owner:TRUSTEES OF TUFTS COLLEGE

Ultrasonic developing composite gel as well as preparation method and application thereof

The invention relates to the technical field of pharmaceutical preparations, in particular to ultrasonic developing composite gel as well as a preparation method and application thereof. The invention provides ultrasonic developing composite gel, which is prepared from the following components in parts by mass: a gel matrix, an ultrasonic developing material and a pharmaceutically acceptable solvent, the concentration of the gel matrix in the ultrasonic developing composite gel is 1 to 500 mg / mL; the concentration of the ultrasonic developing material in the ultrasonic developing composite gel is 1-500 mg / mL; the gel matrix comprises one or more of a temperature sensitive type gel matrix, an injectable type gel matrix and an ion response type gel matrix; the ultrasonic developing material comprises an ultrasonic phase change developer and a high polymer material wrapping the ultrasonic phase change developer, and the ultrasonic developing material is of an ultrasonic developing microbubble structure. The ultrasonic development composite gel can enhance ultrasonic development in the embryo transplantation process and promote adhesion and implantation of an embryo and an endometrium.
Owner:SHANGHAI INST OF ONCOLOGY

Membrane coated nanoparticles for imaging

PCT designated stage expiredWO2025085655A1NanomedicineEmulsion deliveryNanoparticle ComplexMedicine
Provided herein are lipid nanoparticle complex with nanoparticles cloaked in monocyte plasma membrane. The nanoparticles of the lipid nanoparticle complex can be loaded with imaging agents. Also provided are methods of using the lipid nanoparticle complex for targeting and imaging of atherosclerosis in a subject in need thereof.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents

Hydrophilic molecules such as biologics, which can include peptides, proteins, and other biologically-derived materials, can be used as therapeutic agents in medical applications. They can face administration challenges because of poor membrane permeability and rapid clearance from the blood stream. Methods for the formation of a core-shell-brush nanoparticle from an A-B-C triblock copolymer are set forth. A hydrophilic core can contain the biologic and the C Block of the copolymer. The shell can be comprised of the precipitated B Block, and the A Block can form a stabilizing brush layer. The particles can be assembled by sequential precipitations under defined mixing conditions. Presented herein are methods to tune release based on process parameters during particle assembly and triblock characteristics.
Owner:THE TRUSTEES OF PRINCETON UNIV

Protocol for minimizing toxicity of combination dosages and imaging agent for verification

Advantage is taken of the enhanced permeability and retention effect (EPR effect) to shield normal tissue from exposure to combinations of chemotherapeutic agents. Imaging agents that exhibit the enhanced permeability and retention (EPR) effect in solid tumors are useful in mimicking the behavior of chemotherapeutic or other drugs for treatment of said tumor conjugated to carriers of similar size and shape to the carriers of said imaging agents.
Owner:PROLYNX LLC

Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders

ActiveUS12246076B2DiseaseFormulary
There is provided peptidic compounds of Formula I, A or B(Rradn6-[linker]-RL-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-ψ-Xaa9-NH2). Xaa1 is D-Phe, Cpa, D-Cpa, Nal, D-Nal, 2-Nal, or D-2-Nal; Xaa2 is Asn, Gln, Hse, Cit or His. Xaa3 is Trp, Bta, Trp(Me), Trp(7-Me), Trp(6-Me), Trp(5-Me), Trp(4-Me), Trp(2-Me), Trp(7-F), Trp(6-F), Trp(5-F), Trp(4-F), Trp(5-OH), or αMe-Trp. Xaa4 is Ala or Ser. Xaa5 is Val, Cpg, or Tle. Xaa6 is Gly, NMe-Gly, or D-Ala. Xaa7 is His or NMe-His. Xaa8 is Leu or Phe. Xaa9-NH2 is a C-terminally amidated amino acid residue selected from Pro, 4-oxa-L-Pro, Me2 Thz, or Thz. ψ represents a peptide bond or reduced peptide bond joining Xaa8 to Xaa9. Rradn6 is 1-5 radiolabeling groups. There is also provided the use of such compounds as imaging agents or therapeutic agents.
Owner:PROVINCIAL HEALTH SERVICES AUTHORITY +1

PSMA theranostic compounds assembled with tetrazine-trans-cyclooctene ligation

The present disclosure regards PSMA targeting urea-based ligands comprising a PSMA targeting moiety, a linker, and a pyridazine moiety. The PSMA targeting urea-based ligands disclosed are suitable for use as radiopharmaceuticals, either as imaging agents, such as diagnostic agents, or for the treatment of prostate cancer or as theranostic agents.
Owner:UNIVERSITY OF COPENHAGEN +1

Prostate-specific membrane antigen as an imaging biomarker in inflammatory bowel disease

PCT designated stage expiredWO2025038942A1Energy modified materialsComputerised tomographsAntigenImaging biomarker
Disclosed are methods for imaging inflammation associated with inflammatory bowel disease (IBD), including administering to a subject a prostate-specific membrane antigen (PSMA)-targeted imaging agent and taking an image.
Owner:JOHNS HOPKINS UNIVERSITY

Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders

There is provided peptidic compounds of Formula I, A or B(Rradn6-[linker]-RL-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-ψ-Xaa9-NH2). Xaa1 is D-Phe, Cpa, D-Cpa, Nal, D-Nal, 2-Nal, or D-2-Nal; Xaa2 is Asn, Gln, Hse, Cit or His. Xaa3 is Trp, Bta, Trp(Me), Trp(7-Me), Trp(6-Me), Trp(5-Me), Trp(4-Me), Trp(2-Me), Trp(7-F), Trp(6-F), Trp(5-F), Trp(4-F), Trp(5-OH), or αMe-Trp. Xaa4 is Ala or Ser. Xaa5 is Val, Cpg, or Tle. Xaa6 is Gly, NMe-Gly, or D-Ala. Xaa7 is His or NMe-His. Xaa8 is Leu or Phe. Xaa9-NH2 is a C-terminally amidated amino acid residue selected from Pro, 4-oxa-L-Pro, Me2Thz, or Thz. ψ represents a peptide bond or reduced peptide bond joining Xaa8 to Xaa9. Rradn6 is 1-5 radiolabeling groups. There is also provided the use of such compounds as imaging agents or therapeutic agents.
Owner:PROVINCIAL HEALTH SERVICES AUTHORITY +1

Improved aluminum fluoride radiosynthesis of [18f]DK222

A method for preparing an 18F-labeled imaging agent comprising a conjugate of a peptide having a binding specificity for programmed death ligand 1 (PD-L1) and a chelating moiety, and optionally a linker. In representative aspects, the 18F-labeled imaging agent is [18F]-DK222.
Owner:JOHNS HOPKINS UNIVERSITY

Radiolabeled compounds targeting the prostate-specific membrane antigen

A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula (I) or of a salt or a solvate thereof. R1 is —R1aR1b— wherein R1a is absent, —CH2—, —O—, or —S—, and R1b is —CH2— or —CHF—. R2 is —(CH2)3—O—, —(CH2)3—, —(CH2)4—, —CH2—O—(CH2)2—, or —CH2—S—(CH2)2. R3 is ethylene fused to a tricyclic fused ring. L1, L2, L3, L4, L5b L5c, L6 and L7 are linkages (e.g. peptide bonds). Xbr is a branching atom. Rrad is a radiometal chelator. Ralb is an albumin binder. n1, n2, n3, n4, and n5 are integers. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases / conditions.
Owner:PROVINCIAL HEALTH SERVICES AUTHORITY

MRI-agent loaded platelet compositions and methods of preparing and using the same

Provided herein are imaging agent-loaded cryopreserved platelets and platelet derivatives, such as MRI agent-loaded platelets and platelet derivatives, and methods of preparing and using the same. In some embodiments, methods of loading MRI agents into platelets include contacting platelets with an MRI agent and a cell penetrating peptide. In some embodiments, methods of preparing MRI agent-loaded cryopreserved platelets or platelet derivatives in a dried powder, wherein the MRI agent-loaded cryopreserved platelets or the MRI agent-loaded platelet derivatives comprise an MRI agent complex covalently bonded to the surface of the cryopreserved platelets or the platelet derivatives.
Owner:CELLPHIRE INC

Compositions and method for diagnosing and treating alzheimer's disease

Disclosed herein are methods for diagnosing Alzheimer's disease in a subject that involves administering to the subject an imaging agent comprising hyperpolarized pyruvate having a nuclear magnetic resonance (NMR)-detectable nucleus; applying radiation to the brain of the subject, wherein the radiation has a frequency that excites electron spin transitions in the DNP agent at an intensity to polarize the NMR-detectable nucleus; detecting magnetic resonance signals in the brain of the subject from nuclear spin transitions in the NMR-detectable nucleus to produce a spectrum measuring bicarbonate (Bic) and lactate (Lac) metabolites; and calculating a Bic / Lac ratio from the measured metabolites, wherein a reduced Bic / Lac ratio compared to control is an indication that the subject has Alzheimer's disease.
Owner:RGT UNIV OF CALIFORNIA

System and method for identifying an abnormal perfusion pattern

The present disclosure relates to systems and methods for continuously detecting, and optionally classifying, abnormal perfusion patterns in tissue by means of fluorescence imaging. One embodiment relates to a computer implemented method for detecting (and / or identifying) one or more areas having an abnormal perfusion pattern in tissue of a subject, for example during a medical procedure, the method comprising the steps of: continuously acquiring fluorescence images of the tissue, wherein the fluorescence images are associated with a fluorescent output signal correlated with an input signal defined by a series of boluses of at least one fluorescent imaging agent, and wherein the series of boluses is administered with a predefined and / or controlled duration between subsequent boluses, analysing the fluorescence images, identifying at least one tissue area with normal perfusion, defining a normal perfusion pattern (in an intensity domain and) in a time domain, and detecting, in the fluorescence images, possible tissue areas with abnormal (non-normal) perfusion pattern.
Owner:PERFUSION TECH APS